Announcement no. 06/2022 - Coloplast announces the successful issuance of EUR 2.2 billion senior notes under its Euro Medium Term Note programme
Coloplast announces the successful issuance of EUR 2.2 billion senior notes under its Euro Medium Term Note programme
NOT INTENDED FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES. NOT INTENDED FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO ANY PERSON IN ANY JURISDICTION WHERE RELEASE, PUBLICATION OR DISTRIBUTION TO SUCH PERSON IS RESTRICTED BY ANY LAW OR REGULATION APPLICABLE IN SUCH JURISDICTION.
THIS ANNOUNCEMENT IS NOT AN OFFER TO SELL OR ISSUE OR INVITATION TO PURCHASE OR SUBSCRIBE FOR, OR ANY SOLICITATION OF AN OFFER TO PURCHASE OR SUBSCRIBE FOR, ANY SECURITIES.
Coloplast has today raised EUR 2.2 billion in debt financing through the issuance by Coloplast Finance B.V., a newly formed subsidiary of Coloplast, ("Coloplast Finance") of senior unsecured notes in an aggregate principal amount of EUR 2.2 billion (the "Notes") under the Coloplast Euro Medium Term Note programme (the "EMTN Programme"). The Notes are unconditionally and irrevocably guaranteed by Coloplast.
The key details of the Notes are:
Tranche amount: EUR 650 million
- Maturity date: 19 May 2024
- Coupon: 3-month Euribor + 75bp
- Price: 100.203%
- Listing: Nasdaq Copenhagen
Tranche amount: EUR 850 million
- Maturity date: 19 May 2027
- Coupon: 2.250%
- Price: 99.473%
- Listing: Nasdaq Copenhagen
Tranche amount: EUR 700 million
- Maturity date: 19 May 2030
- Coupon: 2.750%
- Price: 99.950%
- Listing: Nasdaq Copenhagen
The net proceeds to Coloplast Finance from the issuance of the Notes will be made available to Coloplast and applied to the refinancing in full of the term loan facility borrowed by Coloplast to finance its acquisition of Atos Medical which closed on 31 January 2022.
The Base Prospectus in respect of the EMTN Programme approved by the Danish Financial Supervisory Authority (Finanstilsynet) is available on Coloplast's website at Bond Investors (coloplast.com). The Final Terms of the Notes will be available on the website in connection with the settlement of the issuance.
Our mission
Making life easier for people
with intimate health care needs
Our values
Closeness... to better understand
Passion... to make a difference
Respect and responsibility... to guide us
Our vision
Setting the global standard
for listening and responding
For further information, please contact
| Investors and analysts Ellen Bjurgert Vice President, Investor Relations Tel. +45 4911 1800 /+45 4911 3376 Email: [email protected] Aleksandra Dimovska Director, Investor Relations Tel. +45 4911 1800 /+45 4911 2458 Email: [email protected] | Press and media Peter Mønster Sr. Media Relations Manager Tel. +45 4911 2623 Email: [email protected] | Address Coloplast A/S Holtedam 1 DK-3050 Humlebaek Denmark Company reg. (CVR) no. 69749917 Website www.coloplast.com |
This announcement is available in a Danish and an English-language version. In the event of discrepancies, the Danish version shall prevail.
Coloplast develops products and services that make life easier for people with very personal and private medical conditions. Working closely with the people who use our products, we create solutions that are sensitive to their special needs. We call this intimate health care. Our business includes Ostomy Care, Continence Care, Wound and Skin Care, Interventional Urology and Voice & Respiratory Care. We operate globally and employ about 14,000 employees.
The Coloplast logo is a registered trademark of Coloplast A/S. © 2022-05.
All rights reserved Coloplast A/S, 3050 Humlebaek, Denmark.
Coloplast A/S Investor Relations Comp. reg. (CVR).
Holtedam 1 Tel. +45 4911 1800 69749917
DK-3050 Humlebaek Fax +45 4911 1555
Denmark www.coloplast.com
Attachment
